| Similar Articles |
|---|
 |
The Motley Fool
December 9, 2008
Brian Orelli |
The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point.   |
The Motley Fool
May 23, 2007
Mike Havrilla |
Cypress Bioscience Comes Full Circle A potential treatment for fibromyalgia sent shares close to $17 today. |
The Motley Fool
October 3, 2011
Harsh Chauhan |
Why This Stock Looks Like a Buy Authorization of another buyback bodes well for Cypress. |
The Motley Fool
September 30, 2005
Stephen D. Simpson |
Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note. |
The Motley Fool
September 10, 2008
Anders Bylund |
Cypress Semi Ditches Its Solar Power Ambitions Cypress Semiconductor will liquidate its entire stake in solar power outfit SunPower. |
The Motley Fool
January 27, 2009
Robert Steyer |
Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit? |
The Motley Fool
August 18, 2011
Ilan Moscovitz |
Cypress Semiconductor Is Cheaper Than You Think Cypress tends to generate more free cash flow than net income, suggesting that the company's stock might be a bit cheaper than many investors realize. |
The Motley Fool
January 12, 2012
Harsh Chauhan |
Why Cypress Still Looks Like A Buy Strong partnerships continue to drive the superconductor maker's growth |
The Motley Fool
October 15, 2004
Tim Beyers |
Taxing Times at Cypress Semiconductor A tax break saves the chip-maker from a big quarterly loss. |
The Motley Fool
September 20, 2010
Anders Bylund |
Better Buy: Cypress or Atmel? Two stocks enter, one stock leaves. |
The Motley Fool
February 25, 2009
Brian Orelli |
Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials. |
The Motley Fool
July 18, 2011 |
Cypress Semiconductor Earnings Preview Investors are on the edge of their seats, hoping that Cypress Semiconductor will top analyst expectations for the fifth consecutive quarter on Thursday, July 21. |
The Motley Fool
January 29, 2009
Brian Orelli |
Lilly's in Need of a Pep Pill Eli Lilly's quarterly earnings report was pretty boring. Some drugs were up and others were down -- the end result was flat sales. |
The Motley Fool
July 25, 2011
Anders Bylund |
What Happened to Cypress? With $0.32 of non-GAAP earnings per share on $255 million in revenue, the maker of touchscreen-control chips and high-speed computer memory beat analyst estimates on both counts. And share prices climbed as much as 6% on the raw results. |
